Friday, September 25, 2026
UBTECH opened a plant in Liuzhou on 12 September that it says will produce more than 10,000 humanoid robots a year, one every ten minutes. Some of the assembly is done by the company's own Walker S units. The interesting number is not the robots. It is the throughput.
Jaguar Land Rover confirmed the cuts on Monday. They are voluntary, they are salaried and management, and they are non-production. This paper said on Saturday that the thing to watch was which functions. That is the answer, and it is not the one the week's reporting had prepared people for.
Eurometal says 300,000 European manufacturing jobs will go before the end of this year, and marked the claim by carrying ten coffins around the European Commission. The stunt makes the figure easy to discount. The cost gap underneath it does not depend on the stunt being fair.
Jaguar Land Rover is expected to confirm 4,000 job cuts on Monday. Pre-tax profit in the last financial year came in at £14m against £2.5bn the year before, on revenue down close to 21 percent to £22.9bn. A fifth off the top line took ninety-nine percent of the profit.
Tirzepatide came off the FDA shortage list in December 2024 and semaglutide in February 2025. Ifosfamide, a decades-old chemotherapy used in curative regimens, is three months into a shortage the FDA expects to run into autumn and European regulators into 2027. Same country, same regulator, same manufacturing base.
GE Appliances is putting a billion dollars into Appliance Park in Louisville, moving dryer production from Mexico and, in an earlier tranche, washer production from China. The company says the investment secures 4,700 manufacturing jobs. The announcement was made jointly with the union.
Four years after a single plant closure emptied American shelves, formula capacity is being added. The largest project by far is Mead Johnson putting several hundred million dollars and 600,000 square feet into the plant it already owns in Zeeland, Michigan. Two much smaller lines are going into Ohio.
Ifosfamide has been in critical shortage for about three months. It is a decades-old chemotherapy used in curative and salvage regimens for sarcoma and testicular cancer, and American supply ran overwhelmingly through one contract plant in Germany, which the FDA had cited in March for recurrent microbial contamination.
America's solar manufacturing pipeline now holds 55.9GW of announced and in-build cell capacity and 41.4GW of modules. Wafers — the step that sits between polysilicon and cells, and without which neither is any use domestically — total 13.3GW across every stage of the pipeline combined.
The US Army's acquisition chief spent a day in August on a howitzer production line in Changwon. The more consequential arrangement is in Arkansas, where a Korean firm has a preliminary lease at a US arsenal to build a $1.3bn plant making nitrocellulose and nitroguanidine — the chemistry every artillery shell is built on, and the part America stopped making.
Eaton is putting $242m and 1,200 jobs into a million square feet in North Little Rock to make customised electrical enclosures, and says the plant will double its US capacity for them. A company does not double capacity for a product that is comfortably supplied.
China's factory gauge says contraction. Its high-tech sub-index says expansion. A single national figure is now averaging two manufacturing economies that are moving in opposite directions.
The Pentagon has signed seven-year framework agreements to triple Patriot interceptor output and quadruple THAAD. The dollar figure is not the interesting clause. The guaranteed minimum annual quantity is.
A would-be maker of a scarce cancer drug may produce it only while the drug is officially in shortage. Succeed at ending the shortage and the permission ends with it, which is a rule that guarantees nobody builds durable capacity.
The medicines that run short are almost never the expensive new ones. They are decades-old generics made on thin margins in a handful of plants, where a single inspection failure removes a meaningful share of world supply.
Subsidy programmes brought cell manufacturing to the continent on a schedule. The electricity those factories need arrives on a different one, set by transmission queues nobody budgeted political attention for.
Industrial equipment outlives its control software by decades. Patching it means stopping production, and the vendor that wrote it may no longer exist.
For a widening set of manufacturers, the machine is now the customer acquisition cost and the maintenance agreement is the business. The shift is rewriting how these companies are valued.
After years of supply chain speeches, the physical evidence has arrived: factory construction, border logistics investment and trade flows reorganizing around proximity.